Cuban HIV vaccine to enter clinical trials

Clinical trials of a new recombinant HIV vaccine from Cuba are expected to begin soon, according to Enrique Iglesias, head of the vaccine development team, and Verena Muizo, director of clinical research at the Biotech and Genetic Engineering Center (CIGB), speaking at the International Biotech Conference-Havana 2012, according to AFP and Sky News. The vaccine, TERAVAC-HIV-1, has been tested in mice, and the next step is to carry out a small Phase I trial in HIV-positive people who have not yet progressed to AIDS. The trial is planned for the second or third quarter. Article | Story

Suggested Articles

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.